NASDAQ:SYBX - Synlogic Stock Price, Forecast & News

Synlogic trades on the NASDAQ under the ticker symbol "SYBX."

Synlogic's stock reverse split on Monday, August 28th 2017. The 1-7 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 25th 2017. An investor that had 100 shares of Synlogic stock prior to the reverse split would have 14 shares after the split.

Synlogic Inc (NASDAQ:SYBX) announced its earnings results on Tuesday, November, 12th. The biotechnology company reported ($0.39) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.48) by $0.09. The biotechnology company had revenue of $0.31 million for the quarter, compared to analyst estimates of $0.46 million. Synlogic had a negative return on equity of 34.49% and a negative net margin of 4,574.82%. View Synlogic's Earnings History.

Synlogic is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Synlogic.

7 Wall Street analysts have issued 1-year target prices for Synlogic's shares. Their forecasts range from $2.00 to $25.00. On average, they expect Synlogic's share price to reach $14.17 in the next twelve months. This suggests a possible upside of 415.2% from the stock's current price. View Analyst Price Targets for Synlogic.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synlogic in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Synlogic.

News headlines about SYBX stock have been trending somewhat positive this week, InfoTrie Sentiment reports. The research firm ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Synlogic earned a coverage optimism score of 2.0 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Synlogic.

Synlogic saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 1,520,000 shares, an increase of 7.8% from the January 15th total of 1,410,000 shares. Based on an average daily volume of 474,400 shares, the days-to-cover ratio is presently 3.2 days. Currently, 8.6% of the company's stock are short sold. View Synlogic's Current Options Chain.

Some companies that are related to Synlogic include Syros Pharmaceuticals (SYRS), Albireo Pharma (ALBO), Lexicon Pharmaceuticals (LXRX), MannKind (MNKD), Aduro BioTech (ADRO), AMAG Pharmaceuticals (AMAG), Wave Life Sciences (WVE), Osmotica Pharmaceuticals (OSMT), Gemphire Therapeutics (GEMP), Evofem Biosciences (EVFM), Bicycle Therapeutics (BCYC), Syndax Pharmaceuticals (SNDX), Advanz Pharma (CXRXF), Avadel Pharmaceuticals (AVDL) and Kamada (KMDA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Synlogic investors own include Reata Pharmaceuticals (RETA), Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Nektar Therapeutics (NKTR), Anavex Life Sciences (AVXL) and Progenics Pharmaceuticals (PGNX).

Synlogic's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.93%), State Street Corp (0.92%), Geode Capital Management LLC (0.78%), Bank of New York Mellon Corp (0.39%), Jacobs Levy Equity Management Inc. (0.31%) and Oxford Asset Management LLP (0.24%). Company insiders that own Synlogic stock include Paul Francis Miller and Richard P Shea. View Institutional Ownership Trends for Synlogic.

SYBX stock was sold by a variety of institutional investors in the last quarter, including State Street Corp. View Insider Buying and Selling for Synlogic.

SYBX stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Jacobs Levy Equity Management Inc., Oxford Asset Management LLP, Bank of New York Mellon Corp, Geode Capital Management LLC, Virtu Financial LLC, Connor Clark & Lunn Investment Management Ltd. and Goldman Sachs Group Inc.. View Insider Buying and Selling for Synlogic.

Shares of SYBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SYBX stock can currently be purchased for approximately $2.75.

Synlogic has a market capitalization of $88.80 million and generates $2.52 million in revenue each year. The biotechnology company earns $-48,440,000.00 in net income (profit) each year or ($2.03) on an earnings per share basis. Synlogic employs 74 workers across the globe.View Additional Information About Synlogic.

The official website for Synlogic is http://www.synlogictx.com/.

Synlogic's mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The biotechnology company can be reached via phone at 617-401-9975 or via email at [email protected]